Despite SU5416′s failure to progress to FDA-approved drug status, it continues to be studied as a potential anti-cancer agent and probe compound for evaluating the effectiveness of VEGFR inhibition strategies for the treatment of cancer. The gene discussed is KDR; the disease is cancer.